Central Precocious Puberty Clinical Trial
Official title:
An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)
The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.
The drug being tested in this study is called leuprorelin acetate depot 3M. Leuprorelin acetate depot 3M will be tested to treat children who have central precocious puberty. This study will look at the efficacy and safety of leuprorelin acetate depot 3M in the treatment of CPP. The study will enroll approximately 80 participants with CPP. Participants with a bodyweight of ≥ 20 kg will receive the recommended dose of leuprorelin acetate depot 3M in a 24 weeks Treatment Period followed by a 12 weeks Post-treatment follow-up period. Participants will be assigned to the following drug administration: • Leuprorelin Acetate Depot 3M 11.25 mg Participants will receive leuprorelin acetate depot 3M 11.25 mg as subcutaneous (SC) injection on Weeks 0, 12, and 24. The gonadotropin-releasing hormone agonist (GnRHa) stimulation, basal luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels will be tested pre-dose of every SC injection of the study drug or at premature termination. This multi-center trial will be conducted in China. The overall time to participate in this study is 38 weeks. Participants will make a follow-up visit to the site at approximately 12 weeks after the last dose of study treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02920515 -
Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty
|
Phase 4 | |
| Completed |
NCT00779103 -
Histrelin Subcutaneous Implant in Children With Central Precocious Puberty
|
Phase 3 | |
| Not yet recruiting |
NCT05341128 -
A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
|
||
| Completed |
NCT04736602 -
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
|
Phase 3 | |
| Completed |
NCT02993926 -
A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
|
||
| Recruiting |
NCT02811471 -
Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
|
Phase 3 | |
| Completed |
NCT03316482 -
Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty
|
Phase 4 | |
| Recruiting |
NCT06129539 -
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty
|
Phase 3 | |
| Completed |
NCT01634321 -
The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty
|
Phase 4 | |
| Terminated |
NCT02006680 -
Markers of Pubertal Suppression During Therapy for Precocious Puberty
|
||
| Completed |
NCT01278290 -
Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls
|
Phase 3 | |
| Completed |
NCT02427958 -
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
|
Phase 4 | |
| Completed |
NCT05029622 -
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
|
Phase 3 | |
| Recruiting |
NCT06025409 -
Evaluate the Efficacy and Safety of DWJ108J
|
Phase 3 | |
| Completed |
NCT01467882 -
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
|
Phase 3 | |
| Recruiting |
NCT00438217 -
Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children
|
Phase 4 |